Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HESTIA5: Ticagrelor in Paediatric Sickle Cell Disease
NCT04293172Phase 3Withdrawn
- Sponsor
- AstraZeneca
- Start
- Jun 2020
- Primary completion
- Oct 2022
- Modality
- Small Molecules
01
Overview
A Phase 3 trial of ticagrelor in sickle cell disease (SCD), sponsored by AstraZeneca. Planned start Jun 2020; status: withdrawn.
02
Drugs
ticagrelor
03
Conditions
sickle cell disease (SCD)
Beyond the preview
Go deeper on NCT04293172.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04293172.